Eyepoint Pharmaceuticals Stock News

EyePoint Pharmaceuticals (NASDAQ:EYPT) is scheduled to announce Q4 earnings results on Thursday, March 3rd, before market open.The consensus EPS Estimate is -$0.51 and the consensus…

WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the live

EyePoint Pharmaceuticals (EYPT) announces eight-month interim data from the DAVIO Phase 1 clinical trial of EYP-1901, for the treatment of wet age-related macular degeneration (wet…

WATERTOWN, Mass., Feb. 12, 2022 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. , a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients | February 12, 2022

WATERTOWN, Mass., Feb. 12, 2022 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced updated interim data from the

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) price on Friday, February 11, rose 1.11% above its previous days close as an upside momentum from buyers pushed the stocks value to $10.00. A look at the stocks price movement, the close in the last trading session was $9.89, moving within a range at $9.48 and $10.19. The beta value EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) Could Slash -550.0% Soon Read More »

EyePoint Pharmaceuticals Inc (EYPT) shares closed this week 21.3% lower than it did at the end of last week. The stock is currently down 18.9% year-to-date, down 9.1% over the past 12 months, and up 419.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.2%. Trading Activity Shares traded as high as $13.97 and as low as $9.50 this week.Trading volume this week was 31.1% lower than the 10-day average and 7.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1053.8% The company's stock price performance over the past 12 months lags the peer average by 2991.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

EyePoint Pharmaceuticals Inc (EYPT) shares closed today 10.6% lower than it did at the end of yesterday. The stock is currently up 15.3% year-to-date, up 36.3% over the past 12 months, and up 646.6% over the past five years. Today, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $14.13 and as low as $11.82 this week.Shares closed 41.3% below its 52-week high and 72.9% above its 52-week low.Trading volume this week was 48.7% lower than the 10-day average and 35.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 849.4% The company's stock price performance over the past 12 months beats the peer average by -5852.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has earned a consensus recommendation of Buy from the five analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage []

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) shares, rose in value on Wednesday, 11/24/21, with the stock price down by -3.63% to the previous days close as strong demand from buyers drove the stock to $16.71. Actively observing the price movement in the last trading, the stock closed the session at $17.34, falling within a range of $16.64 EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT): A Great Stock To Watch Read More »

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has earned an average rating of Buy from the five ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated []

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)s share price gapped down before the market opened on Thursday . The stock had previously closed at $18.40, but opened at $17.33. EyePoint Pharmaceuticals shares last traded at $17.60, with a volume of 4,170 shares. Several research analysts recently issued reports on the stock. Cowen raised their target price on shares []

WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 shares of its common stock. The shares of common stock were sold at a public offering price of $13.75 per share, and the pre-funded warrants were sold at a purchase price of $13.74 per pre-funded warrant, for aggregate gross proceeds of approximately $115.4 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. All of the securities were sold by EyePoint.

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) price on Thursday, November 18, fall -10.92% below its previous days close as a downside momentum from buyers pushed the stocks value to $16.39. A look at the stocks price movement, the close in the last trading session was $18.40. The beta value (5-Year monthly) was 1.35. Turning to its 52-week EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) Shares In 2021: Bullish Prospects Read More »